文献速递肝病

法国慢性乙型肝炎患者2008-2013年预后:一项全国性观察性医院基础研究

Prognosis of patients with chronic hepatitis B in France (2008-2013): A nationwide, observational and hospital-based study.
PubMed 文献 · J Hepatol · 2016-11-05

该研究纳入法国2008至2013年出院的慢性乙型肝炎患者,采用多因素Cox模型分析肝脏及非肝脏危险因素与肝病进展和死亡的关系。结果显示肝病进展、肝移植和死亡分别记录于7479例(15.5%)、433例(8.2%)和5299例(11.0%)患者。合并其他肝脏危险因素者肝病进展风险升高,而无艾滋病(AIDS)的HIV合并感染者预后更好。

要点

  • 肝病进展患者中72.6%存在额外肝脏相关危险因素。
  • 酒精使用障碍的肝病进展校正HR为3.37(95%CI 1.35-1.53)。
  • 无AIDS的HIV合并感染者肝病进展校正HR为0.60(95%CI 0.52-0.70)。

核心结论

  • 在法国2008至2013年,慢性乙型肝炎患者的肝病进展与其他危险因素密切相关。
  • 无AIDS的HIV合并感染者预后更好,提示该组患者获得了更好的照护。
  • 慢性乙型肝炎患者的治疗,包括控制慢性乙型肝炎相关危险因素,在HIV合并感染者中更有效。

研究设计与样本

  • 研究为全国性、观察性、医院基础研究,纳入2008年1月至2013年12月法国本土急性和急性后期照护医院出院的慢性乙型肝炎患者。
  • 采用多因素Cox比例风险模型评估肝脏及非肝脏相关危险因素与肝病进展(终末期肝病或肝细胞癌)和死亡的关系。

主要发现

  • 肝病进展、肝移植和死亡分别记录于7479例(15.5%)、433例(8.2%)和5299例(11.0%)患者。
  • 肝病进展患者中5426例(72.6%)记录到额外肝脏相关危险因素,肝移植或肝脏死亡患者中2699例(75.5%)记录到额外肝脏相关危险因素。
  • 肝病进展的校正HR(95%CI):丁型肝炎病毒合并感染1.44(1.35-1.53),丙型肝炎病毒合并感染1.77(1.68-1.87),酒精使用障碍3.37(3.20-3.55),糖尿病1.40(1.32-1.48),其他罕见慢性肝病病因2.19(1.98-2.42)。
  • 无AIDS的HIV合并感染者肝病进展和院内死亡的校正HR分别为0.60(0.52-0.70)和0.63(0.51-0.78)。
  • 所有肝脏相关危险因素均增加全因死亡风险,尤其在肝病进展后。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: How risk factors associated with chronic hepatitis B (CHB) modify liver disease progression and mortality has been scarcely reported outside of Asia. We aimed to evaluate these risk factors in a French population between 2008 and 2013. METHODS: All individuals discharged with CHB from acute and post-acute care hospitals in Metropolitan France between January 2008 and December 2013 were selected. Associations between liver- and non-liver-related risk factors and both liver disease progression (end-stage liver disease or hepatocellular carcinoma) and mortality were assessed by multivariate Cox proportional hazard models. RESULTS: Overall, liver disease progression, liver transplantation and death were recorded in 7479 (15.5%), 433 (8.2%) and 5299 (11.0%) patients, respectively. An additional liver-related risk factor was recorded in 5426 (72.6%) patients with liver disease progression and 2699 (75.5%) patients with liver transplantation or liver death. Adjusted hazard ratios (95% confidence interval) for liver disease progression of hepatitis D virus co-infection, hepatitis C virus co-infection, alcohol use disorders, diabetes mellitus, and other rare causes of chronic liver disease were 1.44 (1.35-1.53), 1.77 (1.68-1.87), 3.37 (3.20-3.55), 1.40 (1.32-1.48), and 2.19 (1.98-2.42), respectively. All liver-related risk factors increased the risk of all-cause mortality, especially after liver disease progression. Adjusted hazard ratios for liver disease progression and in-hospital mortality of HIV co-infection without acquired immune deficiency syndrome (AIDS) were 0.60 (0.52-0.70) and 0.63 (0.51-0.78), respectively. CONCLUSIONS: In France, 2008-2013, liver disease progression among patients with CHB was closely related to other risk factors. HIV co-infected patients without AIDS had better outcomes, suggesting better care in this group of patients. LAY SUMMARY: In France, 2008-2013, about three-quarters of patients with chronic hepatitis B who progressed to a liver-related complication, including liver transplantation and liver-related death, had an additional liver-related risk factor. Despite a higher prevalence of liver-related risk factors, HIV co-infected patients without AIDS had better outcomes. Prognosis of patients with chronic hepatitis B is closely related to other risk factors. Treatment of patients with chronic hepatitis B, including control of chronic hepatitis B-associated risk factors, is more efficient in HIV co-infected patients.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Mallet V, Hamed K, Schwarzinger M, et al. Prognosis of patients with chronic hepatitis B in France (2008-2013): A nationwide, observational and hospital-based study. J Hepatol. 2016. PMID: 27826056. doi:10.1016/j.jhep.2016.10.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。